Addressing delays in the diagnosis of pheochromocytoma/paraganglioma

References

• Ilias I, Meristoudis G, Notopoulos A. A probabilistic assessment of the diagnosis of paraganglioma/pheochromocytoma based on clinical criteria and biochemical/imaging findings. Hell J Nucl Med. 2015 Jan-Apr;18(1):63–65.
   PubMed Web of Science ®Google Scholar
• Blake MA, Sweeney AT Pheochromocytoma 2018. [updated 2018 Aug 10; 2019 Jun 4]. Available from: https://emedicine.medscape.com/article/124059-overview
   Google Scholar
• Castellano M, Lenders JW, Plouin PF, et al. Management of pheochromocytoma paraganglioma. Eur Soc Hypertens Sci Newsletter. 2010;11:43.
   Google Scholar
• Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005 Aug 20–26;366(9486):665–675.
   PubMed Web of Science ®Google Scholar
• Katabathina VS, Rajebi H, Chen M, et al. Genetics and imaging of pheochromocytomas and paragangliomas: current update. Abdom Radiol (NY); 2019 May 8. [Epub ahead of print].
   Google Scholar
• Jochmanova I, Pacak K. Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends Cancer. 2018 Jan;4(1):6–9.
   PubMed Web of Science ®Google Scholar
• Pamporaki C, Hamplova B, Peitzsch M, et al. Characteristics of pediatric vs adult pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2017 Apr 1;102(4):1122–1132.
   PubMed Web of Science ®Google Scholar
• Young WF, Calhoun DA, Lenders JWM, et al. Screening for endocrine hypertension: An endocrine society scientific statement. Endocr Rev. 2017;38:103–122.
   Web of Science ®Google Scholar
• Rogowski-Lehmann N, Geroula A, Prejbisz A, et al. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocr Connect. 2018;7:1168–1177.
   Web of Science ®Google Scholar
• Soltani A, Pourian M, Davani BM. Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord. 2015;15:6.
   PubMedGoogle Scholar
• Bisogni V, Petramala L, Oliviero G, et al. Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients. Cancers (Basel). 2019 May 12;11(5).
   PubMed Web of Science ®Google Scholar
• Petrak O, Rosa J, Holaj R, et al. Blood Pressure Profile, Catecholamine Phenotype and Target Organ Damage in Pheochromocytoma/Paraganglioma. J Clin Endocrinol Metab. 2019 Apr 22.
   PubMed Web of Science ®Google Scholar
• Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014 May 14;35(19):1245–1254.
   PubMed Web of Science ®Google Scholar
• Kepenekian L, Mognetti T, Lifante JC, et al. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. Eur J Endocrinol. 2016 Oct;175(4):335–344.
   PubMed Web of Science ®Google Scholar
• Geroula A, Deutschbein T, Langton K, et al. Pheochromocytoma and paraganglioma: Clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019 Aug 1. [epub ahead of print]. DOI:10.1530/eje-19-0159
   PubMed Web of Science ®Google Scholar
• Pappachan JM, Buch HN. Endocrine hypertension: A practical approach. Adv Exp Med Biol. 2017;956:215–237.
   PubMed Web of Science ®Google Scholar
• Dong D, Li H. Diagnosis and treatment of pheochromocytoma during pregnancy. J Matern Fetal Neonatal Med. 2014 Dec;27(18):1930–1934.
   PubMed Web of Science ®Google Scholar
• Nieto AJ, Trochez L, Ramirez D, et al. Paraganglioma in pregnancy: interdisciplinary management during pregnancy. Gynecol Endocrinol. 2019;21:1–4.
   Google Scholar
• Casey R, Griffin TP, Wall D, et al. Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. Ann Clin Biochem. 2017 Jan;54(1):170–173.
   PubMed Web of Science ®Google Scholar
• Darr R, Pamporaki C, Peitzsch M, et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf). 2014 Apr;80(4):478–486.
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014 Dec;60(12):1486–1499.
   PubMed Web of Science ®Google Scholar
• Mercado-Asis LB, Wolf KI, Jochmanova I, et al. Pheochromocytoma: A genetic and diagnostic update. Endocr Pract. 2018 Jan;24(1):78–90.
   PubMed Web of Science ®Google Scholar
• Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915–1942.
   PubMed Web of Science ®Google Scholar
• Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002 Mar 20;287(11):1427–1434.
   PubMed Web of Science ®Google Scholar
• Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul). 2017 Jun;32(2):152–161.
   PubMedGoogle Scholar
• Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore). 1991 Jan;70(1):46–66.
   PubMed Web of Science ®Google Scholar
• Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019 Feb;285(2):187–204.
   PubMed Web of Science ®Google Scholar
• Enck RE. The OODA loop. Home Health Care Manag Pract. 2012;24:123–124.
   Google Scholar
• von Lubitz DKJE. Medical readiness for operations other than war: Boyd’s OODA loop and training using advanced distributed simulation technology. Int J Risk Assess Manag. 2008;9:409–432.
   Google Scholar
• Sanogo M, Abatih E, Saegerman C. Bayesian versus frequentist methods for estimating true prevalence of disease and diagnostic test performance. Vet J. 2014 Nov;202(2):204–207.
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005 Apr 23–29;365(9469):1500–1505.
   PubMed Web of Science ®Google Scholar
• Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018 May;178(5):431–437.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016 Aug;175(2):G1–G34.
   PubMed Web of Science ®Google Scholar
• Rao D, Peitzsch M, Prejbisz A, et al. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol. 2017 Aug;177(2):103–113.
   PubMed Web of Science ®Google Scholar
• Clifton-Bligh R. Diagnosis of silent pheochromocytoma and paraganglioma. Expert Rev Endocrinol Metab. 2013 Jan;8(1):47–57.
   PubMedGoogle Scholar
• Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med. 2002 Oct 1;137(7):598–602.
   PubMed Web of Science ®Google Scholar
• Montori VM, Wyer P, Newman TB, et al. Tips for learners of evidence-based medicine: 5. The effect of spectrum of disease on the performance of diagnostic tests. CMAJ. 2005 Aug 16;173(4):385–390.
   PubMed Web of Science ®Google Scholar
• Willis BH. Spectrum bias–why clinicians need to be cautious when applying diagnostic test studies. Fam Pract. 2008 Oct;25(5):390–396.
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Peitzsch M, Kaden D, et al. Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin Chim Acta. 2019;490:46–54.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Doi K, Takeuchi Y, et al. Seasonal variation of urinary excretion of total metanephrines. Clin Chim Acta. 1976 May 3;68(3):241–244.
   PubMed Web of Science ®Google Scholar
• Pamporaki C, Bursztyn M, Reimann M, et al. Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur J Endocrinol. 2014 Mar;170(3):349–357.
   PubMed Web of Science ®Google Scholar
• Ilias I, Meristoudis G. A Bayesian look at the new 2019 guidelines for the imaging of pheochromocytoma/paraganglioma with an emphasis on extra-adrenal disease. Hell J Nucl Med. 2019;22:142.
   PubMed Web of Science ®Google Scholar
• Taieb D, Hicks RJ, Hindie E, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019 Jun 29;46:2112–2137.
   PubMed Web of Science ®Google Scholar
• Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017 Oct 1;96(7):453–461.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Kroiss A, Kumar R, et al. 15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015 Aug;22(4):T135–T145.
   PubMed Web of Science ®Google Scholar
• Barrett JA, Joyal JL, Hillier SM, et al. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010 Jun;25(3):299–308.
   PubMed Web of Science ®Google Scholar
• Chin BB, Kronauge JF, Femia FJ, et al. Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane. J Nucl Med. 2014 May;55(5):765–771.
   PubMed Web of Science ®Google Scholar
• Kroiss AS. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. Wien Med Wochenschr. 2019 Feb;169(1–2):25–32.
   PubMed Web of Science ®Google Scholar
• Kan Y, Zhang S, Wang W, et al. (68)Ga-somatostatin receptor analogs and (18)F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol. 2018 Dec;59(12):1466–1474.
   PubMed Web of Science ®Google Scholar